Primary prevention of cardiotoxicity in cancer patients treated with fluoropyrimidines: a randomized controlled trial

Primary prevention of cardiotoxicity in cancer patients treated with fluoropyrimidines: a randomized controlled trial

Abstract Background Fluoropyrimidines (FP) are the third most used chemotherapeutic drugs administered in solid tumors but have cardiotoxic side effects. We aimed to determine whether pre-chemotherapeutic cardiological assessment and management of cardiovascular risk factors could prevent FP-induced...

Full description

Saved in:
Bibliographic Details
Main Authors: Johanne D. Lyhne, Vibeke B. Hansen, Lone D. Vestergaard, Susanne E. Hosbond, Martin Busk, Mayooran Gnanaganesh, Else Maae, Birgitte M. Havelund, Torben F. Hansen, Signe Timm, Lars H. Jensen, Mads D. Lyhne
Format: Article
Language:English
Published: BMC 2025-05-01
Series:Cardio-Oncology
Subjects:
Cardio-oncology
Cardioprotection
Coronary artery calcium score
Adverse effects
5-FU
Capecitabine
Online Access:https://doi.org/10.1186/s40959-025-00344-3
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s40959-025-00344-3

Similar Items